Case Report
Women with breast cancer are at a higher risk of developing vulvar and vaginal atrophy (VVA). Ospemifene is approved to treat VVA in postmenopausal women with a history of breast cancer after completion of all breast cancer (including adjuvant) treatments. This article examines the background characteristics and outcomes in two postmenopausal women with a history of breast cancer who were treated with ospemifene for VVA.
Case Report
In this case report, outcomes in relation to bone homeostasis, bone mineral density (BMD), and osteopenia– osteoporosis are examined in postmenopausal women during treatment with ospemifene for vulvar and vaginal atrophy (VVA), a component of the genitourinary syndrome of menopause.
Editorial
This editorial article introduces a Special Focus Issue entitled “Treatment of Vulvar and Vaginal Atrophy: Clinical Experience with Ospemifene”. Ospemifene is a selective estrogen receptor modulator indicated for treatment of moderate-to-severe symptomatic vulvar and vaginal atrophy in postmenopausal women who are not candidates for local vaginal estrogen therapy or have contraindications for estrogen products.
Original Research
This article reviews the tolerability of a new delivery system for calcium supplementation, based on the functionalization of calcium carbonate (CaCO3) particles by casein proteins, in a randomized, prospective, double-blind, active comparator clinical trial.
Review
This article reviews the impact of psoriasis during pregnancy, how the disease can be managed pharmacologically during this period according to the available armamentarium, and the possible effects of the therapeutic options for the mother and the foetus.
